Abstract:
Anti-inflammatory agent comprises an active ingredient of benzoyl derivative having the formula ##STR1## WHEREIN R 1  represents hydrogen, halogen, hydroxy, C 1-8  alkyl or C 1-8  alkoxy, 
     R 2  represents hydrogen, halogen, hydroxy, vinyl, C 1-8  alkyl or C 1-8  alkoxy, 
     A represents carbonyl, methylene or a single bond, and 
     n is an integer of 1 to 4.

Description:
BACKGROUND OF THE INVENTION 
     1. Field of the Invention 
     The present invention relates to anti-inflammatory agent which comprises an active ingredient of non-carboxylic benzoyl derivative. 2. Description of the Prior Arts 
     It has been known to use Aspirine, Oxyphenyl butazone, Indomethacin, Phenyl butazone, Ketophenyl butazone, Azapropazone, Azapropazone, Mephenamic acid, Ibufenac, Benzydamine, Aminophylline as non-steroid anti-inflammatory agent. 
     These medicines cause side-effects, gastroenteric disorder, headache, etc.. 
     The inventors have studied various compounds and have found that the specific benzoyl compounds which do not belong to classes of the known compounds in chemical formulae had excellent effects as anti-inflammatory agents and analgesics and also had thrombosis inhibiting effect. 
     SUMMARY OF THE INVENTION 
     It is an object of the present invention to provide novel type anti-inflammatory agent and anti-thrombosis agent which does not cause side-effect. 
     Another object of the invention is to produce novel type anti-inflammatory agent. 
     The objects of the present invention have been attained by providing anti-inflammatory agent which comprises an active ingredient of non-carboxylic benzoyl derivative having the formula ##STR2## wherein R 1  represents hydrogen, halogen, hydroxy, C 1-8  alkyl or C 1-8  alkoxy, 
     R 2  represents hydrogen, halogen, hydroxy, vinyl, C 1-8  alkyl or C 1-8  alkoxy, 
     A represents carbonyl, methylene or a single bond, and n is an integer of 1 to 4. 
     It is preferable to be the active ingredient of benzoyl derivative having the formula ##STR3## wherein R&#39; 1  represents hydrogen, halogen or C 1-8  alkyl, R&#39; 2  represents a substituent at ortho- or para-position which is hydrogen, C 1-8  alkyl or C 1-8  alkoxy, 
     A&#39; represents carbonyl, methylene or a single bond, and n&#39; is an integer of 1 to 3. 
     It is especially preferable to be the active ingredient of ##STR4## wherein R&#34; 1  represents hydrogen or halogen, and R&#34; 2  represents hydrogen, C 3-8  alkyl or C 1-8  alkoxy, especially ##STR5## 
     DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS 
     The benzoyl derivatives used in the invention do not cause side-effect of gastroenteric disorder and had low toxicity and neutral compounds as different from the conventional ones. For example, the benzoyl derivatives having the formula ##STR6## wherein R 1 , R 2 , A and n are defined above; are produced by reacting a compound having the formula ##STR7## wherein R 1  and A are defined above and Hal represents a halogen atom with a compound having the formula ##STR8## wherein R 2  and n are defined above, in the presence of a catalyst and when A is --CH 2  --, A can be converted to --CO-- by reacting an oxidizing agent with the product. 
     The process for producing the benzoyl derivatives will be described in detail. 
     In the production of the compound I wherein A is a single bond or methylene group, the compound I is produced by reacting the compound II wherein A is a single bond or methylene group with the compound III in the presence of a catalyst. 
     Suitable catalysts include anhydrous aluminum chloride, anhydrous zinc chloride, anhydrous stannic chloride and other catalysts for these reactions. 
     Suitable organic solvents such as carbon disulfide, dichloromethane, dichloroethane can be used in the reaction. 
     The reaction is usually completed at 25 to 75° C. with stirring for 3 to 20 hours. 
     After the reaction, the solvent is distilled off and water is added to the residue and the product is extracted with benzene and the solution was washed with a caustic alkali solution, and then with water and dried. The solvent is distilled off to obtain a crude object product (ketone). The purification of the product is carried out by a distillation under a reduced pressure or a recrystallization or the other conventional method. 
     In the production of the compound I wherein A is keto group, the reaction is carried out by using the compound I wherein A is methylene group in the presence of an oxidizing agent such as selenium oxide. In the reaction, suitable solvent such as dioxane, water, ethanol or a mixture thereof can be used. The reaction is usually completed at 110° to 150° C. for 5 to 90 hours. 
     After the reaction, the precipitate is filtered and the solvent is distilled off under a reduced pressure from the filtrate. Water is added to the residue and the product is extracted with chloroform. The chloroform solution is dried and the solvent is distilled off to obtain the crude object compound (benzyl). The purification can be carried out by the conventional method. 
     The anti-inflammatory agent of the invention can be applied by various manners such as oral dose, intravenous injection, intramuscular injection and embrocation. 
     The anti-inflammatory agent of the invention can be used in various forms such as tablet, capsule, injection, syrup, ointment and the other pharmaceutical compositions. 
     The active ingredients can be applied together with the other anti-inflammatory agent, analgesics, thrombus dissolving agent, thrombus formation inhibiting agent, antibiotics, etc.. 
     The dose of the benzoyl derivative (I) is dependent upon the kinds of the object diseases and is usually 0.5 to 1000 mg/kg/day. 
     The benzoyl derivatives (I) had various pharmacological effects as shown in the following tablets. As the anti-inflammatory effect, 2-fluorobenzophenone, 4-n-butyl benzophenone, 4-n-butyl-2&#39;-fluorobenzophenone, 4-n-amyl-2-fluorobenzophenone and 2&#39;-fluoro-2,4,6-trimethyl benzophenone have especially high inhibition rate (ED 50 ). 
     The followings are typical examples of novel compounds of benzoyl derivatives of the invention: 
     2-Fluoro-4&#39;-n-propyl-benzophenone 
     2-Fluoro-4&#39;-n-butyl-benzophenone 
     2-Fluoro-4&#39;-n-amyl-benzophenone 
     2-Fluoro-4&#39;-methoxy-benzophenone 
     2-Fluoro-4&#39;-sec. butyl-benzophenone 
     2-Fluoro-4&#39;-sec.amyl-benzophenone 
     4-Fluoro-4&#39;-n-butyl-benzophenone 
     2-Fluoro-2&#39;,4&#39;,6&#39;-trimethyl-benzophenone 
     2-Chloro-4&#39;-n-butyl-benzophenone 
     2-Bromo-4&#39;-n-amyl-benzophenone 
     2-Bromo-4&#39;-n-octyl-benzophenone 
     2-Fluoro-4&#39;-iso-propyl-benzophenone 
     2-Iodo-4&#39;-n-amyl-benzophenone 
     2-Methyl-4&#39;-n-butyl-benzophenone. 
    
    
     EXAMPLE 1 
     A 2.8 g (0.02 mole) of benzoic acid chloride was dissolved in 30 ml of carbon disulfide and then, 4.0 g (0.03 mole) of anhydrous aluminum chloride was added to the solution. A 2.68 g (0.02 mole) of n-butyl benzene was further added to the mixture with stirring, and the reaction was carried out at room temperature for 18 hours. Carbon disulfide was distilled off from the reaction mixture and water was added and the reaction product was extracted with benzene. The benzene phase was separated and washed with 1N-NaOH and with water and was dried with anhydrous sodium sulfate. The solvent was distilled off to obtain a pale yellow oily product. The oily product was distilled under a reduced pressure to obtain 4.6 g of 4-n-butyl benzophenone having a boiling point of 184° to 188° C./6 mmHg. (yield of 96.8%). 
     EXAMPLE 2 
     A 3.16 g (0.02 mole) of 2-fluoro benzoic acid chloride was dissolved in 30 ml of carbon disulfide and then, 4.0 g (0.03 mole) of anhydrous aluminum chloride was added to the solution. A 2.68 g (0.02 mole) of n-butyl benzene was further added to the mixture with stirring, and the reaction was carried out at room temperature for 18 hours. In accordance with the process of Example 1, the reaction mixture was treated to obtain 3.2 g of 4-n-butyl-2&#39;-fluorobenzophenone having a boiling point of 180° to 190° C./5 mmHg. (yield of 62.5%). 
     EXAMPLE 3 
     A 21.4 g (0.16 mole) of n-butyl benzene and 25.0 g (0.162 mole) of phenyl acetic acid chloride were added to 100 ml of carbon disulfide, and 22.0 g (0.165 mole) of anhydrous aluminum chloride was further added to them with stirring and the reaction was carried out at room temperature for 15 hours. 
     In accordance with the process of Example 1, the reaction mixture was treated and the product was recrystallized from ethanol to obtain 39.0 g of 4-n-butyl-α-phenyl acetophenone having a melting point of 53° to 55° C. which had the formula ##STR9## 
     EXAMPLE 4 
     A 19.7 g (0.78 mole) of 4-n-butyl-α-phenyl acetophenone of Example 3 was dissolved in 200 ml of a mixture of dioxane 5; water 1, and 9.0 g (0.81 mole) of selenium dioxide was added to the solution and the mixture was heated under refluxing to react them for 90 hours. The resulting black precipitate was filtered off and the solvent was distilled off under a reduced pressure from the filtrate. The residue was dissolved in chloroform and the solution was washed with water and was dried. The solvent was distilled off under a reduced pressure and the resulting oily product was distilled under a reduced pressure to obtain 18.7 g of 4-n-butyl benzyl having a boiling point of 240° to 242° C./5 mmHg which had the formula ##STR10## 
     EXAMPLE 5 
     A 3.17 g (0.02 mole) of 2-fluorobenzoic acid chloride was dissolved in 30 ml of carbon bisulfide and then, 3.99 g (0.03 mole) of anhydrous aluminum chloride was added to the solution. A 2.68 g (0.02 mole) of sec-butyl benzene was further added to the mixture with stirring and the reaction was carried out at room temperature for 18 hours. Carbon bisulfide was distilled off from the reaction mixture and water was added and the reaction product was extracted with benzene. The benzene phase was separated washed with 1N-NaOH and with water and was dried with anhydrous sodium sulfate. The solvent was distilled off to obtain a pale yellow oily product. The oily product was distilled under a reduced pressure to obtain 3.9 g of 4-sec-butyl-2&#39;-fluorobenzophenone having a boiling point of 152° to 160° C./5 mmHg. (yield of 76.4%). 
     EXAMPLE 6 
     A 3.17 g (0.02 mole) of 2-fluorobenzoic acid chloride was dissolved in 30 ml of carbon disulfide and then, 3.99 g (0.03 mole) of anhydrous aluminium chloride was added to the solution. A 2.96 g (0.02 mole) of sec-amyl benzene was further added to the mixture with stirring, and the reaction was carried out at room temperature for 18 hours. 
     In accordance with the process of Example 1, the reaction mixture was treated to obtain 4.0 g of 4-sec-amyl-2&#39;-fluorobenzophenone having a boiling point of 150 to 157° C./4 mmHg. (yield of 74%). 
     The properties of the compounds produced in Examples 1 to 6 and the other compounds produced by the same manner are shown. The physical properties are shown in Table 1 and the pharmacological effects are shown in Table 2. 
     In the column for melting points and boiling points in Table 1, the symbol * means the melting point. In the column for IR in Table 1, the symbol * means ν max   nujol  cm -  1. In Table 2, the pharmacological effects and toxicity were measured by the following tests. 
     Anti-inflammatory effect 
     The edema inhibition rates (%) of the samples of the invention were measured in accordance with acute carragheenin edema method described in Nippon Yakurigaku Zatsushi Vol. 56, Page 575 in 1960. 
     The edema was induced by subcutaneous injection of 1% carraheenin suspension in saline to the hind paws of male rats weighing 150 to 180 g. Each sample was orally given at the dosage of 100 mg/kg just before the inoculation of carragheenin. 
     In Table 2, the values shown in brackets show the 50% inhibition rate ED 50  (mg/kg). 
     Analgesic effect 
     In accordance with the method described in Federation Proceedings Vol. 18, Page 412 in 1959, percentage diminition of times of painful stretchings (%) following the intraperitorineal injection of 0.7% acetic acid solution in male mice (weight of 20 to 25 g) were counted. 
     Each sample was orally administrated in the dosage of 100 mg/kg before injection of acetic acid. 
     Blood platelet aggregation inhibiting effect 
     Male rabbits (Japan original white strain 3.3 to 3.6 kg) were anesthetized with Thiopental sodium and blood was sampled from the carotid artery. In order to prevent coaggulation of the blood, 10% by volume of 3.8% sodium citrate aqueous solution was added to the blood. 
     The light transmittances were adjusted to 0% with PRP (supernatant platelet rich plasma separated by centrifugation at 1600 rpm from blood) and to 100% with PPP (supernatant platelet poor plasma separated by centrifugation at 3000 rpm from blood) by using the Blood platelet aggregometer (Model EEl-169, Electroserum Co. England). The platelet aggregation was measured in accordance with the test method described in Federation Proceedings Vol. 26, Page 115 in 1967, using collagen as an aggregation inducer. 
     The percentage inhibition of platelet aggregation was given as the difference in the platelet aggregation rate % between the sample (concentration: 10 -4  mole) and control (saline), with the rate of control adjusted to 100%. 
     Acute toxicity 
     Each sample was dissolved in olive oil or dispersed in 1% Tween 20 aqueous solution. The test was carried out by the oral dose in male mice having a weight of 22 to 25 g. 
     Ten animals were used at each of three or more dosage levels. General appearances and behaviors were observed for 7 days after treatment, and LD 50  was calculated on the basis of mice that succumbed within 72 hours using Van Der Warden method. 
     Inhibiting effect on thrombosis: 
     The inhibiting effects of the samples of the invention on thrombosis were tested by the following test method. 
     SD type male rats (360 to 580 g) were anesthetized by the intraperitoneal injection of Thiopental sodium (67 mg/kg). In accordance with the technique described in Proceeding Society of Experimental Biological Medicine Vol. 139, Pages 548 to 552 in 1972 by Hermann, the by-pass was formed between the left juglar vein and the right carotid artery with a polyethylene tube. 
     A 0.5 ml of 50 μ/ml of the heparin physiological saline was added through the polyethylene tube before the first blood circulation. After the blood circulation for 15 minutes, the circulation was stopped in the middle of the tubing at artery side with a pinch cock. 
     Then, 0.2 ml of the heparin physiological saline was added to remove the blood coagulates on the tubing wall and another new polyethylene tubing filled with the heparin solution and containing a piece of new silk thread was attached between the venous and artery tubing ends. 
     The blood circulation was reestablished by opening the pinch cock. After 15 minutes, the wet weight of thrombus on the silk thread was similarly measured. In the same manner, the third circulation was performed and wet weight of thrombus measured. 
     The amount of thrombus was given by the equation A. ##EQU1## Each sample was suspended in an aqueous solution of sodium carboxymethyl cellulose and the oral dose of the suspension (100 mg/kg) was performed at 5 hours before the first blood circulation. The amount of thrombus after the oral dose of the sample was calculated in the same manner as that of control circulations. 
     The thrombosis inhibition rate was given by the equation B. ##EQU2## The test results are shown in Table 2. 
     
         ______________________________________Composition 1:______________________________________Active ingredient No. 8  100 gFine powdery silica(Solider 101)            100 gCrystalline cellulose    645 gCorn starch              125 gMagnesium stearate        30 g______________________________________ 
    
     The fine powdery silica was admixed with the same amount of the active ingredient No. 8, and the mixture was passed through a 32 mesh sieve. The mixture was admixed with crystalline cellulose, corn starch and magnesium stearate and the components were uniformly mixed by passing through a 32 mesh sieve. The mixture was treated by the tablet machine to form tablets having a diameter of 8 mm and a weight of 200 mg. 
     
         ______________________________________Composition 2:______________________________________Active ingredient No. 3  125 gLactose                  650 gCrystalline cellulose    100 gCorn starch              100 g3% hydroxypropylcellulose aqueous solution                    500 mlMagnesium stearate       10 g______________________________________ 
    
     The lactose, crystalline cellulose and corn starch were admixed with the active ingredient No. 3, and the mixture was passed through a 60 mesh sieve to uniformly mix the components. The mixture was charged in a kneader and 3% hydroxypropyl cellulose aqueous solution was added and the mixture was kneaded. The mixture was granulated by passing through a 16 mesh sieve and was dried at 50° C. and then passed through a 16 mesh sieve to cause uniform particle sizes. The granules were mixed with magnesium stearate and was treated by the tablet machine to form tablets having a diameter of 8 mm and a weight of 200 mg. 
     
         ______________________________________Composition 3:______________________________________Active ingredient No. 119                    100 gFine powdery silica      100 g(Solider 101)Crystalline cellulose    645 gCorn starch              125 gMagnesium stearate        30 g______________________________________ 
    
     The fine powdery silica was admixed with the same amount of the active ingredient No. 119 and the mixture was passed through a 32 mesh sieve. The mixture was admixed with crystalline cellulose, corn starch and magnesium stearate and the components were uniformly mixed by passing through a 32 mesh sieve. The mixture was treated by the tablet machine to form tablets having a diameter of 8 mm and a weight of 200 mg. 
     
         ______________________________________Composition 4:______________________________________Active ingredient No. 136                    125 gLactose                  650 gCrystalline cellulose    100 gCorn starch              100 g3% hydroxypropyl celluloseaqueous solution         500 mlMagnesium stearate        10 g______________________________________ 
    
     The active ingredient No. 136 was uniformly mixed with lactose, crystalline cellulose and corn starch by passing through a 60 mesh sieve. The 3% hydroxypropyl cellulose aqueous solution was added to the mixture in a kneader and the mixture was granulated by passing through a 16 mesh sieve and was dried at 50° C. under air-flow. The dried granules were passed through a 16 mesh sieve to cause uniform particle sizes. The granules were mixed with magnesium stearate and was treated by the tablet machine to form tablets having a diameter of 8 mm and a weight of 200 mg. 
     
                                           Table 1__________________________________________________________________________                  Boiling PointActive                 (° C/mmHg)ingre-                 or       IRdient                  melting  (CO)No. R.sub.1     R.sub.2  A   point (° C)                           ν .sub.max.sup.nujol cm.sup.-1__________________________________________________________________________                           11   2 - CH.sub.3     2,4-diCH.sub.3              single                  155˜160/3                           1660              bond2   &#34;     2,5-diCH.sub.3              &#34;   148˜152/3                           16553   &#34;     2,4,6-triCH.sub.3              &#34;   111˜112*                           1660*4   4-n-C.sub.6 H.sub.13     2,4-diCH.sub.3              &#34;   203˜5/4                           16555   &#34;     4-n-C.sub.4 H.sub.9              &#34;   228/3    16506   &#34;     4-n-C.sub.3 H.sub.7              &#34;   213˜5/3                           16507   2-F   &#34;        &#34;   160˜5/5                           16608   &#34;     4-n-C.sub.4 H.sub.9              &#34;   180˜190/5                           16609   &#34;     4-n-C.sub.5 H.sub.11              &#34;   190˜5/5                           166010  &#34;     2,4-diCH.sub.3              &#34;   150˜5/5                           165511  &#34;     2,4,6-triCH.sub.3              &#34;   155˜160/5                           166012  H     4-OCH.sub.3              CO  180˜190/2                           166013  &#34;     2,4,6-triC.sub.2 H.sub.5              single                  176.5˜178/6.5                           1665              bond14  4-Cl  2,4,6-triCH.sub.3              &#34;   65˜7*                           1660*15  H     2-F      &#34;   190/29   166516  &#34;     2,5-n-diC.sub.3 H.sub.7              &#34;   172˜182/5                           166517  4-CH.sub.3     2,5-n-diC.sub.4 H.sub.9              &#34;   175˜191/2.5                           166018  4-OCH.sub.3     4-n-C.sub.4 H.sub.9              &#34;            164519  H     &#34;        &#34;   184˜188/6                           166020  &#34;     4-n-C.sub.3 H.sub.7              &#34;   161˜167/3.5                           166021  &#34;     4-i-C.sub.3 H.sub.7              &#34;   143˜4/2                           166022  &#34;     4-t-C.sub.4 H.sub.9              &#34;   141˜144/1                           166023  &#34;     4-n-C.sub.5 H.sub.11              &#34;   164˜167/2.5˜3                           166024  &#34;     4-n-C.sub.6 H.sub.13              &#34;   185˜190/3                           165525  &#34;     4-n-C.sub.7 H.sub.15              &#34;   173˜175/2˜2.5                           166026  &#34;     4-n-C.sub.8 H.sub.17              &#34;   185˜190/3                           165527  &#34;     H        &#34;   48˜49.5*                           1660*28  &#34;     4-OCH.sub.3              &#34;   58˜60*                           166029  &#34;     4-n-C.sub.4 H.sub.9              CO  240˜242/5                           166030  &#34;     2,4,6-triCH.sub.3              single                  131˜133/1.5˜2                           1665              bond31  &#34;     2,3,4-triCH.sub.3              &#34;   145.5˜148/2                           166532  &#34;     2,4,5-triCH.sub.3              &#34;   152˜154/3                           166533  4-CH.sub.3     4-C.sub.2 H.sub.5              &#34;   46˜9*                           1645*34  &#34;     4-n-C.sub.3 H.sub.7              &#34;   160˜3/3                           165035  &#34;     4-n-C.sub.4 H.sub.9              &#34;   160˜5/3                           165536  &#34;     4-n-C.sub.6 H.sub.13              &#34;   190˜6/2                           165037  H     2,4-diCH.sub.3              &#34;   120˜122/1˜1.5                           166038  &#34;     2,5-diCH.sub.3              &#34;   132˜134.5/3                           166539  &#34;     4-n-C.sub.4 H.sub.9              CH.sub.2                  53˜55*                           1670*40  2-CH.sub.3     &#34;        single                  157˜163/2                           1665              bond41  &#34;     4-n-C.sub.5 H.sub.11              &#34;   159˜169/1                           166542  H     4-n-OC.sub.4 H.sub.9              &#34;   27˜29*                           1650*43  4-n-C.sub.4 H.sub.9     4-n-C.sub.4 H.sub.9              &#34;   205˜210/3.5                           165044  2-Cl  4-n-C.sub.4 H.sub.9              &#34;   200˜5/5                           166045  4-OCH.sub.3     4-n-C.sub.5 H.sub.11              &#34;            164546  4-n-C.sub.4 H.sub.9     4-F,2-CH.sub.3              &#34;   140˜142/3                           165047  H     H        CH.sub.2                  55*      1670*48  &#34;     4-CH.sub.3              &#34;   104˜106*                           1670*49  &#34;     4-n-C.sub.3 H.sub.7              &#34;   53-54*   1670*50  &#34;     4-n-C.sub.10 H.sub.21              &#34;   50-52*   1670*51  &#34;     4-n-C.sub.11 H.sub.23              &#34;   51-53*   1670*52  &#34;     4-n-C.sub.12 H.sub.25              &#34;   55-58*   1670*53  &#34;     H        CO  95*      1660*54  &#34;     4-CH.sub.3              &#34;   180/1    166055  &#34;     4-C.sub.2 H.sub.5              &#34;   170/1    166056  &#34;     4-n-C.sub.6 H.sub.13              &#34;   200-210/1                           166057  &#34;     4-OCH.sub.3              CH.sub.2                  66-68*   1660*58  &#34;     4-n-OC.sub.3 H.sub.7              &#34;   85-87*   1670*59  &#34;     4-n-OC.sub.5 H.sub.11              &#34;   62-65*   1675*60  4-Cl  4-OCH.sub.3              &#34;   118-119* 1630*61  &#34;     4-n-OC.sub.4 H.sub.9              &#34;   100-101* 1630*62  &#34;     4-n-OC.sub.6 H.sub.13              &#34;   88-89*   1630*63  &#34;     4-n-C.sub.3 H.sub.7              single                  77-78*   1640*              bond64  &#34;     4-n-C.sub.4 H.sub.9              &#34;   62-63*   1640*65  H     4-CH.sub.3              &#34;   45-47*   1640*66  &#34;     4-C.sub.2 H.sub.5              &#34;   133-134/2                           165567  &#34;     4-i-C.sub.4 H.sub.9              &#34;   170-172/4                           165568  &#34;     4-n-C.sub.10 H.sub.21              &#34;   205-210/2                           166069  &#34;     4-n-C.sub.12 H.sub.25              &#34;   215-219/2                           166070  &#34;     4-n-C.sub.9 H.sub.19              &#34;   187-194/25-3                           166571  &#34;     4-n-C.sub.11 H.sub.23              &#34;   199-209/2.5                           166072  &#34;     3,4-diCH.sub.3              &#34;   139-144/1                           166073  &#34;     4-cycloC.sub.6 H.sub.13              &#34;   170-182/1                           166074  &#34;     2,4-diOCH.sub.3              &#34;   87-88*   1660*75  &#34;     2,5-diOCH.sub.3              &#34;   50-52*   1660*76  &#34;     2,4,6-triOCH.sub.3              &#34;   178-179* 1660*77  &#34;     2,5-di-n-C.sub.4 H.sub.9              &#34;   158-169/2                           166078  &#34;     2,3,5,6-tetraCH.sub.3              &#34;   116-118* 1670*79  &#34;     2,3,4,6-tetraCH.sub.3              &#34;   171-172/5.5                           167080  &#34;     2,5-diC.sub.2 H.sub.5              &#34;   161-165/4                           166581  &#34;     4-OC.sub.2 H.sub.5              &#34;   38-39*   1645*82  &#34;     4-CHCH.sub.2              &#34;   oily     166083  4-CH.sub.3     4-CH.sub.3              &#34;   91-93*   1645*84  &#34;     4-n-C.sub.5 H.sub.11              &#34;   170-175/2                           165585  &#34;     4-n-C.sub.7 H.sub.15              &#34;   195-203/3                           165086  &#34;     2,4,6-tri CH.sub.3              &#34;   148-149/2.5                           166587  3-CH.sub.3     4-n-C.sub.3 H.sub.7              &#34;   162-165/4                           165088  &#34;     4-n-C.sub.4 H.sub.9              &#34;   165-170/3                           165089  &#34;     4-n-C.sub.5 H.sub.11              &#34;   175-180/3                           165090  2-CH.sub.3     4-n-C.sub.3 H.sub.7              &#34;   140-147/1.5                           166591  &#34;     2,3,5,6-tetraCH.sub.3              &#34;   105-107* 1660*92  4-OCH.sub.3     4-OCH.sub.3              &#34;   141-142* 1640*93  &#34;     4-n-C.sub.3 H.sub.7              &#34;   oily     164594  4-n-OC.sub.4 H.sub.9     2,4,6-triCH.sub.3              &#34;   190-194/3                           166095  &#34;     4-n-C.sub.4 H.sub.9              &#34;   190-210/3                           165096  4-n-C.sub.3 H.sub.7     2,4-diCH.sub.3              &#34;   185/4    165597  &#34;     2,4,6-triCH.sub.3              &#34;   183-185/4                           165098  &#34;     4-n-C.sub.4 H.sub.9              &#34;   207-210/3.5                           165599  &#34;     4-n-C.sub.5 H.sub.11              &#34;   217-220/4                           1650100 4-n-C.sub.4 H.sub.9     4-n-C.sub.7 H.sub.15              &#34;   oily     1650101 &#34;     4-n-C.sub.8 H.sub.17              &#34;    &#34;       1650102 &#34;     4-n-C.sub.9 H.sub.19              &#34;    &#34;       1650103 4-n-C.sub.6 H.sub.13     2,4,6-triCH.sub.3              &#34;   205-210/4                           1660104 4-OH  4-n-C.sub.3 H.sub.7              &#34;            1630105 &#34;     4-n-C.sub.5 H.sub.11              &#34;            1630106 4-C.sub.2 H.sub.5     4-C.sub.2 H.sub.5              &#34;   47*      1650*107 4-OCH.sub.3     4-C.sub.2 H.sub.5              &#34;   41-43*   1640*108 4-OH  2,4,6-triCH.sub.3              &#34;            1630109 H     4-OH     &#34;   132-135* 1630*110 4-n-C.sub.3 H.sub.7     4-n-C.sub.3 H.sub.7              &#34;   65-67*   1650*111 4-n-C.sub.5 H.sub.11     4-n-C.sub.5 H.sub.11              &#34;   220-222/4                           1650112 4-n-C.sub.2 H.sub.5     4-n-C.sub.3 H.sub.7              &#34;            1660113 H      ##STR11##              &#34;   146-147* 1660*114 4-F   4-F      &#34;   102-105* 1640*115 2-Cl  4-F      &#34;   60-62*   1660*116 2-F   4-OCH.sub.3              &#34;   155-160/5                           1660117 &#34;     4-i-C.sub.3 H.sub.7              &#34;   142-152/5                           1655118 &#34;     4-i-C.sub.4 H.sub.9              &#34;   152-7/4  1660119 &#34;     4-s-C.sub.4 H.sub.9              &#34;   152-160/5                           1660120 &#34;     4-t-C.sub.4 H.sub.9              &#34;   152-157/5                           1660121 &#34;     4-s-C.sub.5 H.sub.11              &#34;   150-7/4  1655122 &#34;     4-t-C.sub.5 H.sub.11              &#34;   160-5/5  1665123 3-F   4-n-C.sub.4 H.sub.9              &#34;   182-7/5  1660124 &#34;     4-n-C.sub.5 H.sub.11              &#34;   185-195/5                           1655125 &#34;     2,4,6-triCH.sub.3              &#34;   oily     1670126 &#34;     2,4-di-CH.sub.3              &#34;   150-3/5  1660127 4-F   4-n-C.sub.4 H.sub.9              &#34;   39-40*   1645*128 &#34;     4-n-C.sub.5 H.sub.11              &#34;   46-7*    1645*129 &#34;     4-n-C.sub.8 H.sub.17              &#34;   32-3*    1645*130 &#34;     2,4-diCH.sub.3              &#34;   149-152/5                           1660131 &#34;     2,4,6-triCH.sub.3              &#34;   150-2/5  1670132 2-Cl  4-n-C.sub.3 H.sub.7              &#34;   188-190/5                           1660133 &#34;     4-n-C.sub.5 H.sub.11              &#34;   200-4/5  1665134 &#34;     4-n-C.sub.8 H.sub.17              &#34;   235-7/5  1665135 &#34;     2,4-diCH.sub.3              &#34;   174-6/5  1660136 4-Cl  4-OCH.sub.3              &#34;   118-9*   1630.sup.N*137 &#34;     4-OC.sub.4 H.sub.9              &#34;   100-1*   1630.sup.N*138 &#34;     4-OC.sub.6 H.sub.13              &#34;   88-9*    1630.sup.N*139 3-Cl  4-n-C.sub.3 H.sub.7              &#34;   27-8*    1670*140 &#34;     4-n-C.sub.5 H.sub.11              &#34;   355-7*   1660*141 &#34;     4-n-C.sub.8 H.sub.17              &#34;   oily     1660142 2-Br  4-n-C.sub.3 H.sub.7              &#34;   39-40*   1670*143 &#34;     4-n-C.sub.4 H.sub.9              &#34;   203-210/5                           1660144 &#34;     4-n-C.sub.5 H.sub.11              &#34;   210-215/5                           1670145 &#34;     4-n-C.sub.8 H.sub.17              &#34;   240-3/4  1665146 &#34;     2,4-diCH.sub.3              &#34;   182-3/5  1660147 &#34;     2,4,6-triCH.sub.3              &#34;   113-4*   1670*148 3-Br  4-n-C.sub.8 H.sub.17              &#34;   240-5/6  1650149 &#34;     2,4-diCH.sub.3              &#34;   180-2/6  1650150 4-Br  4-n-C.sub.3 H.sub.7              &#34;   93-4*    1640*151 &#34;     4-n-C.sub.8 H.sub.17              &#34;   53-4*    1640*152 &#34;     2,4-diCH.sub.3              &#34;   180-5/6  1655153 &#34;     2,4,6-triCH.sub.3              &#34;   70-1*    1660*154 2-I   4-n-C.sub.3 H.sub.7              &#34;   190-7/5  1660155 &#34;     4-n-C.sub.4 H.sub.9              &#34;   202-9/4  1660156 &#34;     4-n-C.sub.5 H.sub.11              &#34;   207-218/4                           1660157 &#34;     4-n-C.sub.8 H.sub.17              &#34;   215-220/4                           1665158 &#34;     2,4-diCH.sub.3              &#34;   192-7/5  1660159 &#34;     2,4,6-triCH.sub.3              &#34;   97-8*    1665*160 3-I   4-n-C.sub.4 H.sub.9              &#34;   45-7*    1645*161 &#34;     4-n-C.sub.8 H.sub.17              &#34;   215-20/4 1655162 &#34;     2,4-diCH.sub.3              &#34;   74-5*    1655*163 &#34;     2,4,6-triCH.sub.3              &#34;   85-6*    1660*164 4-I   4-n-C.sub.8 H.sub.17              &#34;   64-5*    1640*165 &#34;     2,4-diCH.sub.3              &#34;   200-5/7  1655166 &#34;     2,4,6-triCH.sub.3              &#34;   72-3*    1665*__________________________________________________________________________ 
    
     
                       table 2______________________________________Active                          Acuteingre-                    Blood toxicity                                  Thrombo-dient Anti-inf. Analgesic platelet                           LD.sub.50                                  sis inh.No.   (%)       (%)       agg. inh.                           (mg/kg)                                  (%)______________________________________1     36.2 (700)           10.2      21.7  1000   28.52     36.8      13.5      19.5  1000   30.33     40.0 (290)           11.3      17.3  1500   38.34     44.2      16.3      20.5  4000   15.95     46.3      12.1      15.3  5000   20.36     44.2      14.5      17.8  5000   15.97     55.6(78)  15.0      23.0  1500   24.68     82.6(38)  14.8      24.0  1500   38.09     74.6(22)  15.3      14.6  3000   25.310    47.5(90)  20.3      18.5  500    29.711    62.3(22)  13.9      16.5  500    42.912    43.9      10.2      20.1  10000  18.313    38.9(&gt;400)           15.8      14.3  2000   20.514    37.3(130) 19.2      18.1  500    23.315    61.4(65)  18.5      23.2  4000   26.516    45.2(140) 12.4      8.6   1500   21.517    36.3(180) 10.3      17.3  2000   19.518    41.6      20.1      9.3   2000   24.219    63.4(25)  30.1      18.6  2400   7.920    42.7      17.3      36.6  2000   4.121    37.3      16.1      8.6   2000   5.422    36.4      8.2       9.5   2000   7.923    50.4      10.1      13.8  5000   22.324    37.6      47.7      10.5  6000   24.325    40.8      48.6      7.8   8000   22.126    47.2      35.9      3.1   10000  24.827    47.7(120) 13.2      25.7  3700   25.928    44.1      4.2       20.4  &gt;10000 7.329    44.7(130) 2.7       11.1  10000  15.330    64.7(45)  13.4      8.7   1500   44.831    35.4      9.5       18.2  1500   23.532    47.7      26.2      12.4  2000   25.033    43.9      15.5      20.5  3000   28.334    43.1      12.1      16.4  5000   24.535    48.5      17.8      11.3  &gt;10000 26.536    34.8      13.7      15.1  &gt;10000 28.137    39.6      9.8       17.4  1000   5.338    37.5(170) 18.0      20.9  1000   8.339    35.9      23.1      2.6   &gt;10000 15.940    58.1(120) 20.3      11.9  2000   30.341    47.4      14.6      14.4  3000   28.542    35.8      26.8      4.4   3000   10.743    34.0      0         3.5   &gt;10000 8644    57.7(70)  15.6      10.5  2000   35.645    37.8(&gt;400)           12.5      17.7  5000   30.846    43.4(400) 13.4      16.5  2000   34.547    20.9      13.1      18.3         15.648    26.0      12.5      20.5         18.349    10.7      18.2      28.5  8000   13.450    25.5      16.4      8.7   &gt;10000 28.351    24.6      18.3      9.5          13.552    25.5      12.5      6.8          10.153    20.3      14.2      10.1         19.254    25.5      11.3      15.4         20.355    29.0      15.8      23.3         16.456    14.9      20.5      20.3  10000  15.157    16.1      10.3      12.5         6.558    15.3      19.8      20.1         14.659    20.7      22.8      25.6         14.160    13.2      6.3       4.0          12.361    16.7      15.1      15.8         8.562    12.5      10.2      12.3         7.863    11.8      8.2       15.6         6.264    21.4      6.6       28.5  3000   15.965    17.3      10.9      21.0         19.266    34.4      15.7      20.7  2000   20.567    20.0      19.1      18.5  2000   17.368    17.6      5.8       16.5         20.369    12.0      6.7       13.5         12.770    23.2      7.0       17.2         10.071    20.0      9.2       19.5         11.472    29.9      23.4      28.7  1000   30.273    32.1      10.0      20.3  6000   28.874    30.2      24.2      18.5  5000   28.975    29.5      22.0      30.7  5000   29.276    15.7      13.9      16.2  2500   18.477    13.2      10.8      25.1         17.578    12.5      5.4       19.9         20.279    33.2      20.8      26.8  1000   31.580    31.9      16.2      30.3         28.581    15.3      17.6      18.3         20.382    23.8      13.5      20.5         30.183    20.0      12.1      27.6         19.384    28.4      15.3      8.6   10000  16.085    18.7      10.2      18.7         16.286    17.7      8.3       28.3         35.687    18.7      11.2      30.1         25.888    21.6      5.6       24.5         29.389    27.6      4.3       22.6  10000  13.290    19.7      13.7      10.8         15.091    21.4      15.2      14.7         31.092    10.0      11.1      8.9          20.393    20.4      14.7      24.4         26.894    26.6      15.8      27.9  500    37.495    17.1      14.5      30.0         32.396    26.1      18.9      28.5         36.797    13.0      14.7      26.8         37.398    31.9      16.4      28.3  4000   35.499    34.1      15.5      29.5  5000   30.3100   14.0      10.0      22.4         27.6101   23.1      18.3      27.9         31.4102   22.4      15.2      30.4         29.7103   29.7      14.2      29.5  500    35.8104   27.4      13.2      25.3  3000   30.5105   33.6      14.1      24.1  4000   31.4106   26.4      7.3       20.3  1000   20.2107   20.3      13.2      20.3         19.6108   10.5      3.1       28.4         34.7109   12.7      2.6       13.7         20.3110   17.0      10.5      20.5         18.6111   20.6      11.3      10.3         17.3112   14.1      6.7       11.8         15.5113   38.7      14.5      25.8  4000   30.4114   33.2      18.3      26.8  2000   31.1115   14.5      11.8      25.4         27.5______________________________________ 
    
     
                       Table 2&#39;______________________________________Activeingredient                 AcuteNo.          Anti-inf.     toxicity______________________________________116          59.8          4000117          53.3          1500118          32.7          2000119          60.7          2000120          38.3          750121          64.5          3000122          39.3          2000123          38.3          1500124          23.5          3000125          18.1          1000126          27.7          1000127          58.8          5000128          33.6          4000129          38.6          &gt;10000130          37.8          2000131          33.6          2000132          14.9          2000133          38.3          2000134          35.1          3000135          37.2          1000136          13.2          2000137          16.7          2000138          12.5          2500139          11.7          1000140          14.9          1000141          13.8          2000142          38.9          1500143          45.4          1500144          50.0          1500145          60.2          2000146          23.1          1000147          20.4          1000148          36.3          2000149          42.2          500150          14.0          2000151          15.3          2500152          22.6          1500153          27.8          1500154          29.0          &gt;10000155          31.8          &gt;10000156          43.0          &gt;10000157          37.4          &gt;10000158          32.7          2000159          15.9          1000160          10.8          2500161          20.9          5000162          13.0          1500163          16.4          1500164          29.0          &gt;10000165          19.2          5000166          21.5          5000______________________________________ 
    
     Chronic Inflammation 
     (Adjuvant-Induced Arthritis) 
     The effects of (1) 4-n-butyl benzophenone and (2) 4-n-butyl-2&#39;-fluorobenzophenone against adjuvant-induced arthritis were studied. 
     For the study, adult female rats of Sprague Drawley strain weighing approximately 200g were used. All rats received 0.1 ml of a suspension of dry heat-killed tubercle bacilli (human strains, commercial product of Difco Co.) in liquid paraffin (5 mg/ml, w/v) by a single intradermal injection into the tail. 
     The treatment of the animals by the test compounds were started fourteen days after injection of the adjuvant when arthritis developed sufficiently accompanying edema and erythema in paws. Each compound was orally given to animals daily for ten days. Dosage levels employed were 50 and 100 mg/kg/day. Phenylbutazone was used as the reference drug. 
     Evaluations were made using the following parameters. 
     (1) Body weight gain 
     (2) Relative reduction in edema of the hind paws. 
     Results are summarized as follows: 
     
                       Table 1______________________________________Body Weight Gain         No. of               0       6       10 daysCompounds   mg/kg   rats    average______________________________________Positive Control       --      8       202.0 195.9 194.64-n-butyl benzopheone       100     6       229.2 217.5 218.2  &#34;         200     7       214.1 213.3 220.14-n-butyl-2&#39;-fluoro-        50     8       222.6 223.0 232.0benzophenone  &#34;         100     10      211.8 205.8 214.4Phenylbutazone        50     7       215.6 207.7 214.3______________________________________ 
    
     
                       Table 2______________________________________Relative Change of Established Swellingin Hind Paws            Relative Volume            Ratio of Swelling            No. of 6       10 daysCompounds     mg/kg    rats     average______________________________________Positive Control         --       8        1.43  1.424-n-butyl benzophenone         100      6        0.97  1.02  &#34;           200      7        0.76  0.754-n-butyl-2&#39;-fluoro-benzophenone   50      8        0.74  0.76  &#34;           100      10       0.78  0.73Phenylbutazone          50      7        0.75  0.75______________________________________ 
    
     No side effect considered to be related to the test compounds was seen during the study, while phenylbutazone caused the hemorrhage and the ulceration of stomach in most of the animals at dosage levels of 50 and 100 mg/kg/day.